what are semaglutide and tirzepatide vs Semaglutide vs Tirzepatide for Weight

Sci Adv 6:eaay9751 Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA et al (2024) VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2-advanced breast cancer

The FDA approval is based on the OASIS 4 Phase 3 clinical trial a 64-week study of 307 adults with obesity or overweight and at least one weight-related health condition (such as high blood pressure, high cholesterol, or prediabetes), but without type 2 diabetes

Compounding this interval into shorter cycles increases peak concentrations beyond the range studied in efficacy trials, reducing safety predictability

Exercise regularly, too